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Purpose: Gender-based differences exist in the characteristics, management, and 
prognosis of acute coronary syndrome (ACS). However, their impact on prognosis 
remains unclear. We aimed to identify factors causing these differences in Koreans. 
Materials and Methods: We examined 6,636 ACS patients (66.2% males) visiting 
72 Korean hospitals between April-2007 and December-2008. Gender-based differ-
ences in clinical demographics, therapy, and outcomes were analyzed over 6 months. 
Results: Women were older than men [mean (standard deviation, SD) age, 67.6 
(9.8) vs. 60.6 (11.2) years; p<0.001]; had higher rates of hypertension, diabetes mel-
litus, and lack of exercise (p<0.001 for all); and lower rates of obesity, familial histo-
ry of cardiovascular disease (CVD), and smoking (p<0.05 for all). Atypical symp-
toms were more common in women (20.5% vs. 15.1% in men, p<0.001), whereas 
myocardial infarction with ST-segment elevation was less common (17.1% vs. 
27.8%, p<0.001). Mean (SD) time lapse from symptom onset to arrival at hospital 
was longer in women [11.44 (18.19) vs. 8.26 (14.89) hours in men, p<0.001], as was 
the duration of hospitalization [7.58 (7.61) vs. 7.04 (7.72) days, p=0.007]. Fewer 
women underwent revascularization procedures, including thrombolytic therapy, 
balloon angioplasty, stent implantation, and coronary artery bypass grafting (79.4% 
vs. 83.3% men, p<0.001). No significant differences were observed in CVD-related 
death, recurrent ACS, stroke, refractory angina, or rehospitalization for angina. Con-
clusion: Female ACS patients were older than male subjects and had more atypical 
presentation. They arrived at the hospital later than men and had longer hospital 
stays, but less often required revascularization therapy. However, no gender-based 
differences were noted in ACS-related mortality and morbidity.
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INTRODUCTION
Cardiovascular disease (CVD) is a major cause of death worldwide1,2 and the 
third-leading cause of death in Korea, after cancer and cerebrovascular disease. In 
particular, the mortality due to ischemic heart disease has been increasing: in Ko-
rea, this mortality increased from 12.6 in 100,000 individuals in 1994 to 26.3 in Sex-Based Differences among ACS Patients in Korea
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sive procedures for revascularization and drug prescription. 
These studies are an attempt to identify the factor responsible 





This study is a multi-institutional, prospective, observational 
study that was conducted from April 2007 to December 2008 
in 72 Korean hospitals, including Severance Hospital, Yonsei 
University College of Medicine. The subjects were patients 
aged over 19 years who had been diagnosed with ACS with-
in 90 days after the onset of symptoms. Patients with unsta-
ble angina (UA), NSTEMI, and ST-elevation myocardial in-
farction (STEMI) were included, while those undergoing 
clinical trials for drugs were excluded. Prior to the study, all 
subjects consented to the use of their data, and the relevant 
domestic regulations and requirements were complied with. 
A total of 6,636 patients were enrolled in the trial.
For each subject, baseline characteristics were recorded, 
including age, gender, height, weight, ACS classification, 
and medical records upon the onset of ACS (number of ad-
mission, duration of admission, and time lapse from the time 
of symptom onset to that of visiting the hospital). Medical 
history was taken, along with data on risk factors such as 
hypertension, dyslipidemia, diabetes mellitus (DM), obesi-
ty, lack of exercise (not exceeding 30 minutes at a time, less 
than 1-2 times per week of physical activity), smoking, and 
familial history of CVD (angina, MI, and sudden cardiac 
death without obvious cause in parents or siblings). The his-
tory of MI, cerebrovascular disease, coronary disease, pe-
ripheral vascular disease, percutaneous coronary interven-
tion (PCI), and coronary artery bypass grafting (CABG) 
was also recorded. In addition, the history of invasive inter-
ventions (balloon angioplasty, stent grafting, CABG, or im-
plantation of an intra-aortic balloon pump), drug prescription 
records, and manifestation of dependent variables were not-
ed. In this study, clinicians who cared the patient in each cen-
ters decided the type of procedure (PTCA or CABG), based 
on the clinical judgment. There was no follow-up visit sched-
uled in advance, but revisits were planned at a mean (stan-
dard deviation, SD) of 3 (1) months and 6 (1) months after 
the enrollment, and these were recorded as follow-up visits. 
Definition of diseases
CVDs were defined as follows: 
100,000 individuals in 2004.3 Therefore, preventing recur-
rent ischemic heart disease, reducing the number of cases 
of early mortality, and providing appropriate aftercare to 
improve the life expectancy of patients are becoming impor-
tant public health issues.
Despite developments in research on drugs and interven-
tions, many studies conducted on patients with acute coro-
nary syndrome (ACS) over the past 20 years have reported 
that the prevalence of and mortality associated with ACS 
are significantly higher in women than in men.4 In addition, 
clinical trials have shown that the efficacy of antithrombot-
ic agents differs between men and women. For example, in 
the Clopidogrel in Unstable Angina to Prevent Recurrent 
Ischemic Events (CURE) trial,5 the effects of clopidogrel 
on CVD-related mortality, myocardial infarction (MI), and 
stroke showed a significant discrepancy between men and 
women; furthermore, a meta-analysis of 6 studies revealed 
that the use of a glycoprotein (Gp) IIb/IIIa inhibitor decreased 
mortality and the incidence of MI by 19% in male patients 
with non-ST-elevation myocardial infarction (NSTEMI), 
however, increased mortality and the incidence of MI by 
15% in female patients.6
Apart from the biological differences between men and 
women, studies have suggested the existence of gender-
based differences in the prognosis of ACS. It can be attrib-
uted to differences in the diagnostic tests and therapeutic 
methods employed. In practice, female patients undergo 
coronary revascularization and invasive diagnostic proce-
dures less frequently than male patients do,1,2,7 receive nec-
essary procedures much later,8 and less often receive long-
term treatment with beta-blockers that act as anti-ischemic 
agents.1 Therefore, the discrepancy between men and wom-
en in the prognosis of ACS may result from differences in 
the frequency of invasive diagnostic procedures.
These results suggest the need for a study examining the 
reasons for the gender-based differences in mortality and 
morbidity associated with ACS, i.e., biological differences, 
confounding variables (such as diabetes, hypertension, hy-
perlipidemia, and age at onset), or external factors (such as 
invasive intervention and different treatment combinations). 
The primary objective of this study was to examine the dif-
ferences between male and female ACS patients in terms of 
1) the incidence of composite cardiovascular events (CVD-
related death, recurrence of ACS, or stroke) and refractory 
angina, and 2) the rate of rehospitalization for angina. The 
secondary objective was to examine the differences between 
male and female patients in terms of the frequency of inva-Hee Tae Yu, et al.
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stroke), 2) the incidence of refractory angina, and 3) the rate 
of rehospitalization for angina. A Chi-square test or Fisher’s 
exact test was used also to assess whether gender-based dif-
ferences affected the frequency of invasive procedures and 
antithrombotic therapy (clopidogrel loading, treatment with 
Gp IIb/IIIa inhibitors, and anticoagulation), which were per-
formed with a view to achieve revascularization. A p value of 




Of the total 6,636 patients, 4,394 were men (66.2%) and 
2,242 were women (33.8%). Furthermore, 54% of the men 
were 60 years or older, while 79% of the women were in 
this age group (p<0.001).
Upon the diagnosis of ACS, each patient’s history was 
taken, and the risk factors were evaluated. Risk factors were 
evaluated under 7 categories: hypertension, dyslipidemia, 
DM, obesity (body mass index ≥25 kg/m2), lack of exer-
cise, familial history of CVD, and smoking. Women had a 
higher incidence of risk factors: hypertension, dyslipidemia, 
DM, and lack of exercise. The difference between men and 
women was statistically significant for all categories, ex-
cept dyslipidemia (p<0.001 in all cases) (Table 1).
ACS characteristics
The mean (SD) time lapse from the onset of symptoms to 
- CVD-related death-any death for which there was no 
clearly documented nonvascular cause
- MI-2 or more of the following criteria met: 1) ischemic 
chest pain, 2) levels of serum cardiac biomarkers (e.g., tro-
ponin, creatine kinase, creatine kinase-MB isoenzyme, and 
other cardiac enzymes) twice or 3 times their respective 
normal limits in blood samples drawn within 48 hours of 
PCI, and 3) electrocardiogram (EKG) showing changes 
compatible with MI
- Stroke-a new focal neurologic deficit of vascular origin 
lasting more than 24 hours 
- Refractory angina-severe chest pain in an inpatient, last-
ing for longer than 5 minutes, accompanied by EKG changes 
despite adequate medical care, such that the patient requires 
additional procedures such as thrombolysis, cardiac cathe-
terization, implantation of an intra-aortic balloon pump, and 
coronary revascularization
- Significant coronary artery disease-triple vessel disease 
(>50% stenosis of the left descending artery, left circumflex 
artery, and right coronary artery) or >50% stenosis of the 
left main coronary artery
Statistical analysis
Continuous variables are presented as the mean (SD), and 
categorical variables are presented in terms of the frequency 
and percentage of each variable. A Chi-square test or Fisher’s 
exact test was used to analyze the differences between men 
and women in terms of 1) the frequency of composite cardio-









Age (yrs, SD)  62.9 (11.2)   60.6 (11.2)  67.6 (9.8) <0.001*
    <40 (n, %)  135 (2.0)  129 (2.9)    6 (0.3)   <0.001
†
    40-49 (n, %)    746 (11.2)    651 (14.8)  95 (4.2)
    50-59 (n, %) 1,595 (24.0) 1,236 (28.1)  359 (16.0)
    60-69 (n, %) 2,135 (32.2) 1,374 (31.3)  761 (33.9)
    ≥70 (n, %) 2,025 (30.5) 1,004 (22.9) 1,021 (45.5)
Hypertension (n, %) 4,239 (63.9) 2,609 (59.4) 1,630 (72.7) <0.001
†
Dyslipidemia (n, %) 2,113 (31.8) 1,373 (31.2)  740 (33.0)   0.144
†
Diabetes mellitus (n, %) 1,883 (28.4) 1,163 (26.5)  720 (32.1) <0.001
†
Obesity (body mass index ≥25 kg/m
2) (n, %) 2,216 (33.4) 1,535 (34.9)  681 (30.4)   0.003
†
Lack of exercise (n, %) 1,820 (27.4) 1,151 (26.2)  669 (29.8) <0.001
†
Family history of cardiovascular disease (n, %)    713 (10.7)    505 (11.5) 208 (9.3)   0.014
†
Current smoking (n, %) 2,250 (33.9) 2,075 (47.2) 175 (7.8) <0.001
†
Values are presented as means±SD or percentages.
*t-test.
†χ²-test.Sex-Based Differences among ACS Patients in Korea
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PCI. Restenosis occurred in 0.7% men (23 cases) and in 
0.8% women (13 cases, p=0.652). The incidence of stent 
thrombosis and repeat PCI was higher in men, but the dif-
ference was not statistically significant (Table 3).
Treatment
We then examined whether the types of invasive procedures 
performed for revascularization differed between men and 
women. Revascularization was performed for 83.3% of men 
(3,658 of 4,393 cases) and 79.4% of women (1,779 of 2,242 
cases) following the diagnosis of ACS (p<0.001). Among 
men, the order of frequency (allowing redundancy) of the 
types of revascularization procedures was balloon angio-
plasty (3,562 cases, 97.4%), followed by stent grafting 
(3,450 cases, 94.3%) and thrombolytic therapy (190 cases, 
5.2%). Among women, the order was balloon angioplasty 
(1,728 cases, 97.1%), followed by stent grafting (1,669 cas-
es, 93.8%) and CABG (63 cases, 3.5%).
Antithrombotic therapy was administered to 92.2% of men 
(4,051 of 4,394 cases) and 91.0% of women (2,041 of 2,242 
cases) (p=0.104). Clopidogrel loading was used for 79.0% 
of men (3,470 cases) and 78.1% of women (1,752 cases; 
p=0.437); Gp IIb/IIIa inhibitors, for 7.3% of men (320 cases) 
and 4.3% of women (97 cases; p<0.001); and anticoagula-
tion therapy, for 70.6% of men (3,101 cases) and 67.3% of 
women (1,509 cases; p=0.006) (Table 4).
DISCUSSION
   
In this study, we examined the gender-based differences in 
terms of 1) the incidence of composite cardiovascular events, 
2) the frequency with which different invasive revasculariza-
arrival at the hospital was 9.2 (16.0) hours, i.e., 8.3 (14.9) 
hours for men and 11.4 (18.2) hours for women (p<0.001). 
The mean (SD) duration of hospitalization was 7.2 (7.7) 
days for men and 7.6 (7.6) days for women (p=0.007). Fur-
thermore, women showed a higher percentage of atypical 
symptoms upon the onset of ACS than men did (20.5% vs. 
15.1%, p<0.001).
A total of 6,635 ACS diagnosis were further classified as 
UA (3,518 cases, 53.0%), STEMI (1,604 cases, 24.2%), and 
NSTEMI (1,513 cases, 22.8%). Among the 4,393 men, the 
order of frequency of ACS classification was UA (2,161 cas-
es, 49.2%), followed by STEMI (1,221 cases, 27.8%) and 
NSTEMI (1,011 cases, 23.0%). Among the 2,242 women 
with ACS, the order of frequency was UA (1,357 cases, 
60.5%), followed by NSTEMI (502 cases, 22.4%) and STE-
MI (383 cases, 17.1%). The difference between men and 
women in terms of ACS classification was statistically signif-
icant (p<0.001) (Table 2).
Prognosis
The incidence of composite cardiovascular events (CVD-
related death, recurrence of ACS, and stroke) among all pa-
tients diagnosed with ACS throughout the study period was 
recorded and analyzed to assess gender-based differences.
Gender-based analysis of the prognosis of ACS patients 
over 6 months (from the first to the third visit) showed that 
the frequency of CVD-related death, recurrent ACS, stroke, 
refractory angina, rehospitalization for angina, and CABG 
was higher in women. The gender-based difference in prog-
nosis was small and not statistically significant.
The patients who underwent stent grafting as part of the 
revascularization procedure were followed up to determine 
the incidence of restenosis, stent thrombosis, and repeat 








Time lapse from symptom onset to  
  arrival at the hospital (hrs, SD)
    9.2 (16.0)     8.3 (14.9)   11.5 (18.2) <0.001*
Duration of hospitalization (days, SD)   7.2 (7.7)   7.0 (7.8)   7.6 (7.6)    0.007*
Atypical symptoms (n, %) 1,125 (17.0)    665 (15.1)    460 (20.5) <0.001
†
Type of ACS
    Unstable angina (n, %) 3,518 (53.0) 2,161 (49.2) 1,357 (60.5) <0.001
†
    Non-ST-elevation MI (n, %) 1,513 (22.8) 1,011 (23.0)    502 (22.4)
    ST-elevation MI (n, %) 1,604 (24.2) 1,221 (27.8)    383 (17.1)
ACS, acute coronary syndrome; MI, myocardial infarction.
Values are presented as means±SD or percentages.
*t-test.
†χ²-test.Hee Tae Yu, et al.
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mortality after ACS.9-15 
In our study, analysis of the incidence of composite car-
diovascular events in ACS patients revealed that women 
had a higher incidence of composite cardiovascular events, 
refractory angina, and rehospitalization for angina than 
men, despite the fact that the study involved twice as many 
male patients as female patients. However, this gender-based 
difference was not statistically significant. The incidence of 
compound cardiovascular events generally did not exceed 
1% for both men and women, but this may be because the 
study had a relatively short follow-up period of 6 months. 
Longer follow-up is required to determine the long-term 
outcomes. 
The average time lapse from the onset of symptoms to 
arrival at the hospital was 8 hours for men, but 11 hours for 
tion procedures were performed, and 3) the medications 
used. Our purpose was to determine whether the gender-
based differences in morbidity and mortality caused by ACS 
are attributable to biological differences, confounding fac-
tors (such as variations in the incidence of DM, hyperten-
sion, dyslipidemia, and age at onset), or external factors (in-
cluding differences in the frequency of invasive procedures 
or medication).
Various studies on patients with acute MI have reported 
that women have higher in-hospital mortality and short-
term mortality than men.9-16 Studies on gender-based differ-
ences in unstable angina or infarction without ST elevation 
yielded similar results.17 However, after adjusting for age 
and differences in various coexisting conditions, many stud-
ies concluded that gender is not an independent predictor of 










  death (n, %)
30 (0.5) 19 (0.4) 11 (0.5) 0.738
Recurrent ACS (n, %) 38 (0.6) 25 (0.6) 13 (0.6) 0.956
Stroke (n, %) 16 (0.2)   8 (0.2)   8 (0.4) 0.170
Refractory angina (n, %) 28 (0.4) 15 (0.3) 13 (0.6) 0.156
Rehospitalization for angina (n, %) 58 (0.9) 37 (0.8) 21 (0.9) 0.695










Restenosis (n, %) 36 (0.7) 23 (0.7) 13 (0.8) 0.652
Stent thrombosis (n, %)   4 (0.1)   3 (0.1)   1 (0.1) 1.000
Repeat percutaneous coronary 
  intervention (n, %)
65 (1.3) 45 (1.3) 20 (1.2) 0.216
ACS, Acute Coronary Syndrome.
Values are presented as means±SD or percentages.









Revascularization (n, %) 5,437 (81.9) 3,658 (83.3) 1,779 (79.4) <0.001
Thrombolytic therapy (n, %)  247 (4.5) 190 (5.2)    57 (3.2)
Balloon angioplasty (n, %) 5,290 (97.3) 3,562 (97.4) 1,728 (97.1)
Stent grafting (n, %) 5,119 (94.2) 3,450 (94.3) 1,669 (93.8)
Intra-aortic balloon pump (n, %)    93 (1.7)    61 (1.7)    32 (1.8)
Coronary artery bypass grafting (n, %)  216 (4.0)  153 (4.2)    63 (3.5)
Others (n, %)    35 (0.6)    22 (0.6)    13 (0.7)
Antithrombotic therapy (n, %) 6,092 (91.8) 4,051 (92.2) 2,041 (91.0)   0.104
Clopidogrel loading (n, %) 5,222 (78.7) 3,470 (79.0) 1,752 (78.1)   0.437
GP IIb/IIIa inhibitor treatment (n, %)  417 (6.3)  320 (7.3)    97 (4.3) <0.001
Anticoagulation therapy (n, %) 4,610 (69.5) 3,101 (70.6) 1,509 (67.3)   0.006
Values are presented as means±SD or percentages.Sex-Based Differences among ACS Patients in Korea
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ating the gender, clinical symptoms, and treatment out-
comes of ACS patients have shown that female ACS pa-
tients are usually older than male patients, and that a history 
of diabetes, hypertension, and congestive heart disease is 
significantly more common in women. In contrast, howev-
er, a history of MI or smoking is significantly less common 
in women.28 
In this study, we analyzed the gender-based differences in 
each risk factor for ACS and found that, while a higher per-
centage of men showed obesity, familial history of heart 
disease, and smoking as risk factors, a higher percentage of 
women showed hypertension, diabetes, and lack of exer-
cise. Furthermore, 54.1% of all the male subjects were ≥60 
years old, as opposed to 79.5% of the female subjects. There-
fore, biological differences as well as risk factors such as 
dyslipidemia, hypertension, and diabetes may play a role in 
the gender-based differences in ACS.
In conclusion, there were no significant gender-based dif-
ferences in mortality and morbidity due to ACS. Even if 
such differences exist, they cannot be explained by a single 
factor (biological, confounding, or external). Rather, several 
factors seem to concomitantly contribute to gender-based 
differences.
This study has limitations representing the overall gender-
based differences in ACS patients in Korea. Nonetheless, it 
provides insights into the demographics of ACS patients, as-
sociated risk factors and improvements, trends related to re-
vascularization and antithrombotic therapy, thus providing 
helpful input for the management of ACS patients.
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